Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Related Citations for PubMed (Select 10481813)

1.

Is the societal perspective in cost-effectiveness analysis useful for decision makers?

Russell LB, Fryback DG, Sonnenberg FA.

Jt Comm J Qual Improv. 1999 Sep;25(9):447-54. Review.

PMID:
10481813
2.

The once and future application of cost-effectiveness analysis.

Berger ML.

Jt Comm J Qual Improv. 1999 Sep;25(9):455-61. Review.

PMID:
10481814
3.

Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.

Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L.

Value Health. 2010 Jan-Feb;13(1):3-7. doi: 10.1111/j.1524-4733.2009.00663.x. Epub 2009 Oct 28.

PMID:
19874571
4.

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.

Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P.

Value Health. 2007 Sep-Oct;10(5):336-47.

PMID:
17888098
5.

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.

Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC.

JAMA. 1996 Oct 9;276(14):1172-7. Review.

PMID:
8827972
6.

Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.

Garrison LP Jr, Mansley EC, Abbott TA 3rd, Bresnahan BW, Hay JW, Smeeding J.

Value Health. 2010 Jan-Feb;13(1):8-13. doi: 10.1111/j.1524-4733.2009.00660.x. Epub 2009 Oct 23.

PMID:
19883405
7.

Risk management frameworks for human health and environmental risks.

Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, McColl S.

J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. Review.

PMID:
14698953
8.

A dollar is a dollar is a dollar--or is it?

Brouwer WB, van Exel NJ, Baltussen RM, Rutten FF.

Value Health. 2006 Sep-Oct;9(5):341-7.

PMID:
16961552
9.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
10.
11.

The impact of market-based 'reform' on cultural values in health care.

Curtin LL.

Semin Nurse Manag. 1999 Dec;7(4):198-202. Review.

PMID:
11013589
12.
13.
14.

Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.

Adang E, Voordijk L, Jan van der Wilt G, Ament A.

Health Policy. 2005 Oct;74(2):146-56. Epub 2005 Jan 26.

PMID:
16153475
15.

Ethics of allocating intensive care unit resources.

Lanken PN, Terry PB, Osborne ML.

New Horiz. 1997 Feb;5(1):38-50. Review.

PMID:
9017677
16.

Has the time come for cost-effectiveness analysis in US health care?

Bryan S, Sofaer S, Siegelberg T, Gold M.

Health Econ Policy Law. 2009 Oct;4(Pt 4):425-43. doi: 10.1017/S1744133109004885. Epub 2009 Feb 9.

PMID:
19203399
17.
18.

Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.

Gafni A, Birch S.

Soc Sci Med. 2006 May;62(9):2091-100. Epub 2005 Dec 1.

PMID:
16325975
19.

Variation in average costs among federally sponsored state-organized cancer detection programs: economies of scale?

Mansley EC, Duñet DO, May DS, Chattopadhyay SK, McKenna MT.

Med Decis Making. 2002 Sep-Oct;22(5 Suppl):S67-79.

PMID:
12369233
20.

Who should manage care? The case for patients.

Veatch RM.

Kennedy Inst Ethics J. 1997 Dec;7(4):391-401.

PMID:
11655372
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk